Ontology type: schema:ScholarlyArticle Open Access: True
2011-04-08
AUTHORSAndrea Kuendgen, Gesine Bug, Oliver G. Ottmann, Detlef Haase, Julie Schanz, Barbara Hildebrandt, Kathrin Nachtkamp, Judith Neukirchen, Ariane Dienst, Rainer Haas, Ulrich Germing, Norbert Gattermann
ABSTRACT5-azacytidine (AZA) has become standard treatment for patients with higher-risk myelodysplastic syndrome (MDS). Response rate is about 50% and response duration is limited. Histone deactylase (HDAC) inhibitors are attractive partners for epigenetic combination therapy. We treated 24 patients with AZA (100 mg/m2, 5 days) plus valproate (VPA; continuous dosing, trough serum level 80–110 μg/ml). According to WHO classification, 5 patients had MDS, 2 had MDS/MPD, and 17 had acute myeloid leukemia (AML). Seven patients (29%) had previously received intensive chemotherapy, and five had previous HDAC inhibitor treatment. The overall response rate was 37% in the entire cohort but significantly higher (57%) in previously untreated patients, especially those with MDS (64%). Seven (29%) patients achieved CR (29%) and two PR (8%), respectively. Hematological CR was accompanied by complete cytogenetic remission according to conventional cytogenetics in all evaluable cases. Some patients also showed complete remission according to FISH on bone marrow mononuclear cells and CD34+ peripheral blood cells, as well as by follow-up of somatic mitochondrial DNA mutations. Four additional patients achieved at least marrow remissions. Factors influencing response were AML (vs. MDS), marrow blast count, pretreatment, transfusion dependency, concomitant medication with hydroxyurea, and valproic acid (VPA) serum level. This trial is the first to assess the combination of AZA plus VPA without additional ATRA. A comparatively good CR rate, relatively short time to response, and the influence of VPA serum levels on response suggest that VPA provided substantial additional benefit. However, the importance of HDAC inhibitors in epigenetic combination therapy can only be proven by randomized trials. More... »
PAGES389-399
http://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9
DOIhttp://dx.doi.org/10.1007/s13148-011-0031-9
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1034458391
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/22704349
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Kuendgen",
"givenName": "Andrea",
"id": "sg:person.01022105364.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany",
"id": "http://www.grid.ac/institutes/grid.7839.5",
"name": [
"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany"
],
"type": "Organization"
},
"familyName": "Bug",
"givenName": "Gesine",
"id": "sg:person.0660354231.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660354231.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany",
"id": "http://www.grid.ac/institutes/grid.7839.5",
"name": [
"Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany"
],
"type": "Organization"
},
"familyName": "Ottmann",
"givenName": "Oliver G.",
"id": "sg:person.01051501512.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany",
"id": "http://www.grid.ac/institutes/grid.7450.6",
"name": [
"Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany"
],
"type": "Organization"
},
"familyName": "Haase",
"givenName": "Detlef",
"id": "sg:person.0754465332.53",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany",
"id": "http://www.grid.ac/institutes/grid.7450.6",
"name": [
"Department of Hematology/Oncology, Georg-August-University G\u00f6ttingen, G\u00f6ttingen, Germany"
],
"type": "Organization"
},
"familyName": "Schanz",
"givenName": "Julie",
"id": "sg:person.01252562364.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252562364.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institute of Human Genetics, Heinrich-Heine-University, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Institute of Human Genetics, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Hildebrandt",
"givenName": "Barbara",
"id": "sg:person.01320675564.15",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Nachtkamp",
"givenName": "Kathrin",
"id": "sg:person.01367010764.53",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367010764.53"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Neukirchen",
"givenName": "Judith",
"id": "sg:person.0643404664.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Dienst",
"givenName": "Ariane",
"id": "sg:person.0673303715.21",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673303715.21"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Haas",
"givenName": "Rainer",
"id": "sg:person.01127414674.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Germing",
"givenName": "Ulrich",
"id": "sg:person.01362464041.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "Norbert",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.leu.2404796",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003666698",
"https://doi.org/10.1038/sj.leu.2404796"
],
"type": "CreativeWork"
}
],
"datePublished": "2011-04-08",
"datePublishedReg": "2011-04-08",
"description": "Abstract5-azacytidine (AZA) has become standard treatment for patients with higher-risk myelodysplastic syndrome (MDS). Response rate is about 50% and response duration is limited. Histone deactylase (HDAC) inhibitors are attractive partners for epigenetic combination therapy. We treated 24 patients with AZA (100\u00a0mg/m2, 5\u00a0days) plus valproate (VPA; continuous dosing, trough serum level 80\u2013110\u00a0\u03bcg/ml). According to WHO classification, 5 patients had MDS, 2 had MDS/MPD, and 17 had acute myeloid leukemia (AML). Seven patients (29%) had previously received intensive chemotherapy, and five had previous HDAC inhibitor treatment. The overall response rate was 37% in the entire cohort but significantly higher (57%) in previously untreated patients, especially those with MDS (64%). Seven (29%) patients achieved CR (29%) and two PR (8%), respectively. Hematological CR was accompanied by complete cytogenetic remission according to conventional cytogenetics in all evaluable cases. Some patients also showed complete remission according to FISH on bone marrow mononuclear cells and CD34+ peripheral blood cells, as well as by follow-up of somatic mitochondrial DNA mutations. Four additional patients achieved at least marrow remissions. Factors influencing response were AML (vs. MDS), marrow blast count, pretreatment, transfusion dependency, concomitant medication with hydroxyurea, and valproic acid (VPA) serum level. This trial is the first to assess the combination of AZA plus VPA without additional ATRA. A comparatively good CR rate, relatively short time to response, and the influence of VPA serum levels on response suggest that VPA provided substantial additional benefit. However, the importance of HDAC inhibitors in epigenetic combination therapy can only be proven by randomized trials.",
"genre": "article",
"id": "sg:pub.10.1007/s13148-011-0031-9",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1042271",
"issn": [
"1868-7075",
"1868-7083"
],
"name": "Clinical Epigenetics",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "2",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "2"
}
],
"keywords": [
"acute myeloid leukemia",
"myelodysplastic syndrome",
"epigenetic combination therapy",
"serum levels",
"combination therapy",
"myeloid leukemia",
"response rate",
"poor\u2010risk myelodysplastic syndromes",
"high-risk myelodysplastic syndrome",
"valproic acid serum levels",
"bone marrow mononuclear cells",
"better CR rate",
"VPA serum levels",
"marrow blast count",
"overall response rate",
"histone deactylase inhibitors",
"complete cytogenetic remission",
"MDS/MPD",
"peripheral blood cells",
"HDAC inhibitor treatment",
"marrow mononuclear cells",
"hematological CR",
"intensive chemotherapy",
"untreated patients",
"complete remission",
"marrow remission",
"concomitant medications",
"blast count",
"cytogenetic remission",
"additional patients",
"transfusion dependency",
"CR rate",
"randomized trials",
"entire cohort",
"evaluable cases",
"standard treatment",
"mononuclear cells",
"combination of azacytidine",
"response duration",
"substantial additional benefit",
"valproic acid",
"patients",
"inhibitor treatment",
"HDAC inhibitors",
"remission",
"mitochondrial DNA mutations",
"blood cells",
"somatic mitochondrial DNA mutations",
"conventional cytogenetics",
"azacytidine",
"syndrome",
"therapy",
"leukemia",
"treatment",
"VPA",
"trials",
"additional benefit",
"DNA mutations",
"inhibitors",
"valproate",
"cells",
"response",
"medications",
"chemotherapy",
"cohort",
"CD34",
"ATRA",
"rate",
"levels",
"hydroxyurea",
"duration",
"count",
"cytogenetics",
"pretreatment",
"mutations",
"combination",
"short time",
"factors",
"cases",
"benefits",
"attractive partners",
"acid",
"MPD",
"partners",
"PR",
"classification",
"time",
"importance",
"fish",
"Cr",
"influence",
"dependency"
],
"name": "Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid",
"pagination": "389-399",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1034458391"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s13148-011-0031-9"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"22704349"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s13148-011-0031-9",
"https://app.dimensions.ai/details/publication/pub.1034458391"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:00",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_541.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s13148-011-0031-9"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13148-011-0031-9'
This table displays all metadata directly associated to this object as RDF triples.
246 TRIPLES
21 PREDICATES
119 URIs
109 LITERALS
7 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s13148-011-0031-9 | schema:about | anzsrc-for:11 |
2 | ″ | ″ | anzsrc-for:1102 |
3 | ″ | ″ | anzsrc-for:1112 |
4 | ″ | schema:author | N10c9adee7c7f4a0d80bbb536d23fb987 |
5 | ″ | schema:citation | sg:pub.10.1038/sj.leu.2404796 |
6 | ″ | schema:datePublished | 2011-04-08 |
7 | ″ | schema:datePublishedReg | 2011-04-08 |
8 | ″ | schema:description | Abstract5-azacytidine (AZA) has become standard treatment for patients with higher-risk myelodysplastic syndrome (MDS). Response rate is about 50% and response duration is limited. Histone deactylase (HDAC) inhibitors are attractive partners for epigenetic combination therapy. We treated 24 patients with AZA (100 mg/m2, 5 days) plus valproate (VPA; continuous dosing, trough serum level 80–110 μg/ml). According to WHO classification, 5 patients had MDS, 2 had MDS/MPD, and 17 had acute myeloid leukemia (AML). Seven patients (29%) had previously received intensive chemotherapy, and five had previous HDAC inhibitor treatment. The overall response rate was 37% in the entire cohort but significantly higher (57%) in previously untreated patients, especially those with MDS (64%). Seven (29%) patients achieved CR (29%) and two PR (8%), respectively. Hematological CR was accompanied by complete cytogenetic remission according to conventional cytogenetics in all evaluable cases. Some patients also showed complete remission according to FISH on bone marrow mononuclear cells and CD34+ peripheral blood cells, as well as by follow-up of somatic mitochondrial DNA mutations. Four additional patients achieved at least marrow remissions. Factors influencing response were AML (vs. MDS), marrow blast count, pretreatment, transfusion dependency, concomitant medication with hydroxyurea, and valproic acid (VPA) serum level. This trial is the first to assess the combination of AZA plus VPA without additional ATRA. A comparatively good CR rate, relatively short time to response, and the influence of VPA serum levels on response suggest that VPA provided substantial additional benefit. However, the importance of HDAC inhibitors in epigenetic combination therapy can only be proven by randomized trials. |
9 | ″ | schema:genre | article |
10 | ″ | schema:isAccessibleForFree | true |
11 | ″ | schema:isPartOf | N1b48774896f54541b4b0f1dbcd09ca8e |
12 | ″ | ″ | Nfc524190f0b543af8a42d6dda8ba975d |
13 | ″ | ″ | sg:journal.1042271 |
14 | ″ | schema:keywords | ATRA |
15 | ″ | ″ | CD34 |
16 | ″ | ″ | CR rate |
17 | ″ | ″ | Cr |
18 | ″ | ″ | DNA mutations |
19 | ″ | ″ | HDAC inhibitor treatment |
20 | ″ | ″ | HDAC inhibitors |
21 | ″ | ″ | MDS/MPD |
22 | ″ | ″ | MPD |
23 | ″ | ″ | PR |
24 | ″ | ″ | VPA |
25 | ″ | ″ | VPA serum levels |
26 | ″ | ″ | acid |
27 | ″ | ″ | acute myeloid leukemia |
28 | ″ | ″ | additional benefit |
29 | ″ | ″ | additional patients |
30 | ″ | ″ | attractive partners |
31 | ″ | ″ | azacytidine |
32 | ″ | ″ | benefits |
33 | ″ | ″ | better CR rate |
34 | ″ | ″ | blast count |
35 | ″ | ″ | blood cells |
36 | ″ | ″ | bone marrow mononuclear cells |
37 | ″ | ″ | cases |
38 | ″ | ″ | cells |
39 | ″ | ″ | chemotherapy |
40 | ″ | ″ | classification |
41 | ″ | ″ | cohort |
42 | ″ | ″ | combination |
43 | ″ | ″ | combination of azacytidine |
44 | ″ | ″ | combination therapy |
45 | ″ | ″ | complete cytogenetic remission |
46 | ″ | ″ | complete remission |
47 | ″ | ″ | concomitant medications |
48 | ″ | ″ | conventional cytogenetics |
49 | ″ | ″ | count |
50 | ″ | ″ | cytogenetic remission |
51 | ″ | ″ | cytogenetics |
52 | ″ | ″ | dependency |
53 | ″ | ″ | duration |
54 | ″ | ″ | entire cohort |
55 | ″ | ″ | epigenetic combination therapy |
56 | ″ | ″ | evaluable cases |
57 | ″ | ″ | factors |
58 | ″ | ″ | fish |
59 | ″ | ″ | hematological CR |
60 | ″ | ″ | high-risk myelodysplastic syndrome |
61 | ″ | ″ | histone deactylase inhibitors |
62 | ″ | ″ | hydroxyurea |
63 | ″ | ″ | importance |
64 | ″ | ″ | influence |
65 | ″ | ″ | inhibitor treatment |
66 | ″ | ″ | inhibitors |
67 | ″ | ″ | intensive chemotherapy |
68 | ″ | ″ | leukemia |
69 | ″ | ″ | levels |
70 | ″ | ″ | marrow blast count |
71 | ″ | ″ | marrow mononuclear cells |
72 | ″ | ″ | marrow remission |
73 | ″ | ″ | medications |
74 | ″ | ″ | mitochondrial DNA mutations |
75 | ″ | ″ | mononuclear cells |
76 | ″ | ″ | mutations |
77 | ″ | ″ | myelodysplastic syndrome |
78 | ″ | ″ | myeloid leukemia |
79 | ″ | ″ | overall response rate |
80 | ″ | ″ | partners |
81 | ″ | ″ | patients |
82 | ″ | ″ | peripheral blood cells |
83 | ″ | ″ | poor‐risk myelodysplastic syndromes |
84 | ″ | ″ | pretreatment |
85 | ″ | ″ | randomized trials |
86 | ″ | ″ | rate |
87 | ″ | ″ | remission |
88 | ″ | ″ | response |
89 | ″ | ″ | response duration |
90 | ″ | ″ | response rate |
91 | ″ | ″ | serum levels |
92 | ″ | ″ | short time |
93 | ″ | ″ | somatic mitochondrial DNA mutations |
94 | ″ | ″ | standard treatment |
95 | ″ | ″ | substantial additional benefit |
96 | ″ | ″ | syndrome |
97 | ″ | ″ | therapy |
98 | ″ | ″ | time |
99 | ″ | ″ | transfusion dependency |
100 | ″ | ″ | treatment |
101 | ″ | ″ | trials |
102 | ″ | ″ | untreated patients |
103 | ″ | ″ | valproate |
104 | ″ | ″ | valproic acid |
105 | ″ | ″ | valproic acid serum levels |
106 | ″ | schema:name | Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid |
107 | ″ | schema:pagination | 389-399 |
108 | ″ | schema:productId | N9baf3a28e6884197a104c6e75baece5a |
109 | ″ | ″ | Nae125ed8a90f4111b53e91a98190e810 |
110 | ″ | ″ | Nb676e5bf4afc492fa7b13c8fd06b6267 |
111 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1034458391 |
112 | ″ | ″ | https://doi.org/10.1007/s13148-011-0031-9 |
113 | ″ | schema:sdDatePublished | 2022-08-04T17:00 |
114 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
115 | ″ | schema:sdPublisher | Nbc01a5afcfc14da6a66f8a2d7f657322 |
116 | ″ | schema:url | https://doi.org/10.1007/s13148-011-0031-9 |
117 | ″ | sgo:license | sg:explorer/license/ |
118 | ″ | sgo:sdDataset | articles |
119 | ″ | rdf:type | schema:ScholarlyArticle |
120 | N10c9adee7c7f4a0d80bbb536d23fb987 | rdf:first | sg:person.01022105364.01 |
121 | ″ | rdf:rest | N47990c72fb6843ec842fbdeda3e33db2 |
122 | N1ab849f488784cb9bb44d32fc564e6be | rdf:first | sg:person.01273447501.34 |
123 | ″ | rdf:rest | rdf:nil |
124 | N1b48774896f54541b4b0f1dbcd09ca8e | schema:issueNumber | 2 |
125 | ″ | rdf:type | schema:PublicationIssue |
126 | N47990c72fb6843ec842fbdeda3e33db2 | rdf:first | sg:person.0660354231.27 |
127 | ″ | rdf:rest | Ne3ab05cea1d14ff594be51c90d7968c6 |
128 | N4cd9ad66173f4536ba840c6c070375fa | rdf:first | sg:person.0643404664.08 |
129 | ″ | rdf:rest | N736c6868742444c9b1504c55316173cd |
130 | N5432a9f6c49f41a9b2af40c0c4b09f0a | rdf:first | sg:person.01320675564.15 |
131 | ″ | rdf:rest | Nbbb0f9814f4e42f790a611275ae2d2c4 |
132 | N5ef5435a42c3481b8e21de66f760893e | rdf:first | sg:person.01252562364.34 |
133 | ″ | rdf:rest | N5432a9f6c49f41a9b2af40c0c4b09f0a |
134 | N72206512e5f54c76b8f88eb7970bb829 | rdf:first | sg:person.01362464041.20 |
135 | ″ | rdf:rest | N1ab849f488784cb9bb44d32fc564e6be |
136 | N736c6868742444c9b1504c55316173cd | rdf:first | sg:person.0673303715.21 |
137 | ″ | rdf:rest | Na6a99d018ddf4f839d1bde5197706cdd |
138 | N9baf3a28e6884197a104c6e75baece5a | schema:name | pubmed_id |
139 | ″ | schema:value | 22704349 |
140 | ″ | rdf:type | schema:PropertyValue |
141 | Na6a99d018ddf4f839d1bde5197706cdd | rdf:first | sg:person.01127414674.14 |
142 | ″ | rdf:rest | N72206512e5f54c76b8f88eb7970bb829 |
143 | Nae125ed8a90f4111b53e91a98190e810 | schema:name | doi |
144 | ″ | schema:value | 10.1007/s13148-011-0031-9 |
145 | ″ | rdf:type | schema:PropertyValue |
146 | Nb676e5bf4afc492fa7b13c8fd06b6267 | schema:name | dimensions_id |
147 | ″ | schema:value | pub.1034458391 |
148 | ″ | rdf:type | schema:PropertyValue |
149 | Nbbb0f9814f4e42f790a611275ae2d2c4 | rdf:first | sg:person.01367010764.53 |
150 | ″ | rdf:rest | N4cd9ad66173f4536ba840c6c070375fa |
151 | Nbc01a5afcfc14da6a66f8a2d7f657322 | schema:name | Springer Nature - SN SciGraph project |
152 | ″ | rdf:type | schema:Organization |
153 | Nc1f97ec0bc084293bb2d7940ca12ac7c | rdf:first | sg:person.0754465332.53 |
154 | ″ | rdf:rest | N5ef5435a42c3481b8e21de66f760893e |
155 | Ne3ab05cea1d14ff594be51c90d7968c6 | rdf:first | sg:person.01051501512.14 |
156 | ″ | rdf:rest | Nc1f97ec0bc084293bb2d7940ca12ac7c |
157 | Nfc524190f0b543af8a42d6dda8ba975d | schema:volumeNumber | 2 |
158 | ″ | rdf:type | schema:PublicationVolume |
159 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
160 | ″ | schema:name | Medical and Health Sciences |
161 | ″ | rdf:type | schema:DefinedTerm |
162 | anzsrc-for:1102 | schema:inDefinedTermSet | anzsrc-for: |
163 | ″ | schema:name | Cardiorespiratory Medicine and Haematology |
164 | ″ | rdf:type | schema:DefinedTerm |
165 | anzsrc-for:1112 | schema:inDefinedTermSet | anzsrc-for: |
166 | ″ | schema:name | Oncology and Carcinogenesis |
167 | ″ | rdf:type | schema:DefinedTerm |
168 | sg:journal.1042271 | schema:issn | 1868-7075 |
169 | ″ | ″ | 1868-7083 |
170 | ″ | schema:name | Clinical Epigenetics |
171 | ″ | schema:publisher | Springer Nature |
172 | ″ | rdf:type | schema:Periodical |
173 | sg:person.01022105364.01 | schema:affiliation | grid-institutes:grid.411327.2 |
174 | ″ | schema:familyName | Kuendgen |
175 | ″ | schema:givenName | Andrea |
176 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01 |
177 | ″ | rdf:type | schema:Person |
178 | sg:person.01051501512.14 | schema:affiliation | grid-institutes:grid.7839.5 |
179 | ″ | schema:familyName | Ottmann |
180 | ″ | schema:givenName | Oliver G. |
181 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051501512.14 |
182 | ″ | rdf:type | schema:Person |
183 | sg:person.01127414674.14 | schema:affiliation | grid-institutes:grid.411327.2 |
184 | ″ | schema:familyName | Haas |
185 | ″ | schema:givenName | Rainer |
186 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14 |
187 | ″ | rdf:type | schema:Person |
188 | sg:person.01252562364.34 | schema:affiliation | grid-institutes:grid.7450.6 |
189 | ″ | schema:familyName | Schanz |
190 | ″ | schema:givenName | Julie |
191 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252562364.34 |
192 | ″ | rdf:type | schema:Person |
193 | sg:person.01273447501.34 | schema:affiliation | grid-institutes:grid.411327.2 |
194 | ″ | schema:familyName | Gattermann |
195 | ″ | schema:givenName | Norbert |
196 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34 |
197 | ″ | rdf:type | schema:Person |
198 | sg:person.01320675564.15 | schema:affiliation | grid-institutes:grid.411327.2 |
199 | ″ | schema:familyName | Hildebrandt |
200 | ″ | schema:givenName | Barbara |
201 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15 |
202 | ″ | rdf:type | schema:Person |
203 | sg:person.01362464041.20 | schema:affiliation | grid-institutes:grid.411327.2 |
204 | ″ | schema:familyName | Germing |
205 | ″ | schema:givenName | Ulrich |
206 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20 |
207 | ″ | rdf:type | schema:Person |
208 | sg:person.01367010764.53 | schema:affiliation | grid-institutes:grid.411327.2 |
209 | ″ | schema:familyName | Nachtkamp |
210 | ″ | schema:givenName | Kathrin |
211 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367010764.53 |
212 | ″ | rdf:type | schema:Person |
213 | sg:person.0643404664.08 | schema:affiliation | grid-institutes:grid.411327.2 |
214 | ″ | schema:familyName | Neukirchen |
215 | ″ | schema:givenName | Judith |
216 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08 |
217 | ″ | rdf:type | schema:Person |
218 | sg:person.0660354231.27 | schema:affiliation | grid-institutes:grid.7839.5 |
219 | ″ | schema:familyName | Bug |
220 | ″ | schema:givenName | Gesine |
221 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660354231.27 |
222 | ″ | rdf:type | schema:Person |
223 | sg:person.0673303715.21 | schema:affiliation | grid-institutes:grid.411327.2 |
224 | ″ | schema:familyName | Dienst |
225 | ″ | schema:givenName | Ariane |
226 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673303715.21 |
227 | ″ | rdf:type | schema:Person |
228 | sg:person.0754465332.53 | schema:affiliation | grid-institutes:grid.7450.6 |
229 | ″ | schema:familyName | Haase |
230 | ″ | schema:givenName | Detlef |
231 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754465332.53 |
232 | ″ | rdf:type | schema:Person |
233 | sg:pub.10.1038/sj.leu.2404796 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1003666698 |
234 | ″ | ″ | https://doi.org/10.1038/sj.leu.2404796 |
235 | ″ | rdf:type | schema:CreativeWork |
236 | grid-institutes:grid.411327.2 | schema:alternateName | Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany |
237 | ″ | ″ | Institute of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany |
238 | ″ | schema:name | Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225, Düsseldorf, Germany |
239 | ″ | ″ | Institute of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany |
240 | ″ | rdf:type | schema:Organization |
241 | grid-institutes:grid.7450.6 | schema:alternateName | Department of Hematology/Oncology, Georg-August-University Göttingen, Göttingen, Germany |
242 | ″ | schema:name | Department of Hematology/Oncology, Georg-August-University Göttingen, Göttingen, Germany |
243 | ″ | rdf:type | schema:Organization |
244 | grid-institutes:grid.7839.5 | schema:alternateName | Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany |
245 | ″ | schema:name | Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany |
246 | ″ | rdf:type | schema:Organization |